EUR 0.64
(-6.16%)
Year | Net Income | Net Income Growth |
---|---|---|
2023 | -22.06 Million EUR | 4.94% |
2022 | -23.2 Million EUR | -53.33% |
2021 | -15.13 Million EUR | -68.6% |
2020 | -8.97 Million EUR | 25.78% |
2019 | -12.09 Million EUR | 2.06% |
2018 | -12.35 Million EUR | -27.5% |
2017 | -9.68 Million EUR | -30.67% |
2016 | -7.41 Million EUR | -73.56% |
2015 | -4.27 Million EUR | -38.62% |
2014 | -3.08 Million EUR | -87.09% |
2013 | -1.64 Million EUR | -66.79% |
2012 | -987.33 Thousand EUR | -102.67% |
2011 | -487.16 Thousand EUR | 0.0% |
Year | Net Income | Net Income Growth |
---|---|---|
2024 Q2 | -13.89 Million EUR | 0.0% |
2023 Q2 | -12.28 Million EUR | 0.0% |
2023 Q4 | -9.77 Million EUR | 0.0% |
2023 FY | -22.06 Million EUR | 4.94% |
2022 Q2 | -12.26 Million EUR | 0.0% |
2022 FY | -23.2 Million EUR | -53.33% |
2022 Q4 | -10.94 Million EUR | 0.0% |
2021 Q2 | -6.24 Million EUR | 0.0% |
2021 Q4 | -8.89 Million EUR | 0.0% |
2021 FY | -15.13 Million EUR | -68.6% |
2020 Q4 | -4.25 Million EUR | 0.0% |
2020 Q2 | -4.71 Million EUR | 0.0% |
2020 FY | -8.97 Million EUR | 25.78% |
2019 Q2 | -5.46 Million EUR | 0.0% |
2019 FY | -12.09 Million EUR | 2.06% |
2019 Q4 | -6.63 Million EUR | 0.0% |
2018 Q2 | -6.13 Million EUR | 0.0% |
2018 Q4 | -6.21 Million EUR | 0.0% |
2018 FY | -12.35 Million EUR | -27.5% |
2017 FY | -9.68 Million EUR | -30.67% |
2017 Q4 | -5.13 Million EUR | 0.0% |
2017 Q2 | -4.55 Million EUR | 0.0% |
2016 FY | -7.41 Million EUR | -73.56% |
2016 Q2 | -4.29 Million EUR | 0.0% |
2016 Q4 | -3.11 Million EUR | 0.0% |
2015 FY | -4.27 Million EUR | -38.62% |
2015 Q4 | -2.74 Million EUR | 0.0% |
2015 Q2 | -1.52 Million EUR | 0.0% |
2014 FY | -3.08 Million EUR | -87.09% |
2014 Q4 | -1.86 Million EUR | -142.55% |
2014 Q3 | -770.24 Thousand EUR | 36.49% |
2014 Q2 | -1.21 Million EUR | -57.45% |
2014 Q1 | -770.24 Thousand EUR | 0.0% |
2013 Q3 | -411.68 Thousand EUR | 0.0% |
2013 FY | -1.64 Million EUR | -66.79% |
2013 Q4 | -770.24 Thousand EUR | -87.09% |
2013 Q1 | -411.68 Thousand EUR | 0.0% |
2013 Q2 | -411.68 Thousand EUR | 0.0% |
2012 Q4 | -411.68 Thousand EUR | -66.79% |
2012 FY | -987.33 Thousand EUR | -102.67% |
2012 Q1 | -246.83 Thousand EUR | 0.0% |
2012 Q2 | -246.83 Thousand EUR | 0.0% |
2012 Q3 | -246.83 Thousand EUR | 0.0% |
2011 FY | -487.16 Thousand EUR | 0.0% |
2011 Q4 | -246.83 Thousand EUR | 0.0% |
Name | Net Income | Net Income Difference |
---|---|---|
ABIONYX Pharma SA | -3.51 Million EUR | -527.158% |
ABIVAX Société Anonyme | -147.74 Million EUR | 85.066% |
Adocia SA | -21.16 Million EUR | -4.26% |
Aelis Farma SA | -5.07 Million EUR | -334.49% |
Biophytis S.A. | -17.02 Million EUR | -29.587% |
Advicenne S.A. | -7.03 Million EUR | -213.802% |
genOway Société anonyme | 1.56 Million EUR | 1507.486% |
IntegraGen SA | -171.39 Thousand EUR | -12772.54% |
Medesis Pharma S.A. | -3.95 Million EUR | -457.228% |
Neovacs S.A. | -8.74 Million EUR | -152.342% |
NFL Biosciences SA | -3.74 Million EUR | -489.068% |
Plant Advanced Technologies SA | 79.16 Thousand EUR | 27968.742% |
Quantum Genomics Société Anonyme | -3.17 Million EUR | -595.799% |
Theranexus Société Anonyme | -6.82 Million EUR | -223.134% |
TME Pharma N.V. | -6.73 Million EUR | -227.545% |
Valbiotis SA | -7.36 Million EUR | -199.449% |
TheraVet SA | -1.57 Million EUR | -1304.68% |
Valerio Therapeutics Société anonyme | -20.34 Million EUR | -8.452% |
argenx SE | -272.91 Million EUR | 91.916% |
BioSenic S.A. | -28.77 Million EUR | 23.332% |
Celyad Oncology SA | -8.44 Million EUR | -161.167% |
DBV Technologies S.A. | -67.26 Million EUR | 67.201% |
Galapagos NV | 211.69 Million EUR | 110.422% |
Genfit S.A. | -28.89 Million EUR | 23.64% |
GeNeuro SA | -14.75 Million EUR | -49.511% |
Hyloris Pharmaceuticals SA | -15.38 Million EUR | -43.455% |
Innate Pharma S.A. | -7.57 Million EUR | -191.458% |
Inventiva S.A. | -110.42 Million EUR | 80.02% |
MaaT Pharma SA | -19.71 Million EUR | -11.9% |
MedinCell S.A. | -25.03 Million EUR | 11.88% |
Nanobiotix S.A. | -39.7 Million EUR | 44.425% |
Onward Medical N.V. | -36.18 Million EUR | 39.019% |
Oryzon Genomics S.A. | -3.35 Million EUR | -558.031% |
OSE Immunotherapeutics SA | -23 Million EUR | 4.085% |
Oxurion NV | -18.96 Million EUR | -16.313% |
Pharming Group N.V. | -9.75 Million EUR | -126.139% |
Poxel S.A. | -35.09 Million EUR | 37.123% |
GenSight Biologics S.A. | -26.22 Million EUR | 15.853% |
Transgene SA | -22.32 Million EUR | 1.185% |
Financière de Tubize SA | 88.15 Million EUR | 125.029% |
UCB SA | 343 Million EUR | 106.432% |
Valneva SE | -101.42 Million EUR | 78.247% |
Vivoryon Therapeutics N.V. | -28.34 Million EUR | 22.153% |